<?xml version="1.0" encoding="UTF-8"?>
<p>In Japan, more than 20 rapid influenza diagnostic tests (RIDTs) are marketed. These are considered core tools for determining whether to start treatment with anti-influenza drugs [
 <xref rid="pone.0231217.ref001" ref-type="bibr">1</xref>]. During influenza epidemics, Japanese clinicians routinely use RIDTs in the examination of patients with influenza-like illness (ILI), and patients with positive test results, including otherwise healthy individuals, are treated with anti-influenza drugs [
 <xref rid="pone.0231217.ref002" ref-type="bibr">2</xref>]. In Japan, approximately 20–40 million RIDT kits are used every season [
 <xref rid="pone.0231217.ref003" ref-type="bibr">3</xref>], which costs approximately 200–400 million US dollars per year.
</p>
